Current perspectives of lipoproteins in cardiovascular and cerebrovascular diseases

doi:10.3877/cma.j.issn.2095-5820.2014.02.005

Abstract

Abstract:

Dyslipidemia is an independent risk factor for coronary heart disease and cerebral ischemic stroke. The traditional lipid testing has been widely used in prevention and treatment of cardiovascular and cerebrovascular disease. With the development of measurement technique, lipoprotein subfraction detection separates two of the commonly measured lipoprotein fractions, high density lipoprotein (HDL) and low density lipoprotein (LDL),into subfractions based on their size, density, and/or electrical charge. Notably, different subfractions have different biological functions and contentious association with these diseases. A calculation of non-high density lipoprotein-cholesterol (non-HDL-C), which presents the total level of cholesterol containing atherogenicapolipoprotein B, has a good implication prospect especially in the high-risk individuals. Although the novel testing is promising predictor for cardiovascular diseases in clinical practice, further study, including pathophysiological mechanisms,quantitative contribution to disease, standardized measurement and nomenclature, are urgently required.

Key words: Lipoproteins, Cardiovascular and cerebrovascular disease

Yahui Lin, Xi Chen. Current perspectives of lipoproteins in cardiovascular and cerebrovascular diseases[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2014, 02(02): 88-92.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2014.02.005

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2014/V02/I02/88

References 34

1	卫生部心血管病防治研究中心. 中国心血管病报告. 卫生部心血管病防治研究中，2012.
2	中华心血管病杂志编辑委员会. 中国心血管病预防指南[J]. 中华心血管病杂志, 2011, 39(1):3-22.
3	中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组. 中国急性缺血性脑卒中诊治指南[J]. 中华神经科杂志，2010,43(2): 146-153.
4	中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007,35(5):390-419.
5	Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events[J]. Clinl chem, 2011,57(3):392-410.
6	Camont L, Chapman MJ, Kontush A. Biological activities of hdl subpopulations and their relevance to cardiovascular disease[J]. Trends Mol Med, 2011,17(10): 594-603.
7	Superko HR, Pendyala L, Williams PT, et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease[J]. J Clin Lipidol, 2012,6(6): 496-523.
8	Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial[J]. Circulation,2006,113(12):1556-1563.
9	Parish S, Offer A, Clarke R, et al. Lipids and lipoproteins and risk of different vascular events in the mrc/bhf heart protection study[J].Circulation, 2012,125(20): 2469-2478.
10	范杰, 齐玥, 赵冬. 高密度脂蛋白颗粒亚型与心血管病事件关系的荟萃分析[J]. 中华心血管病杂志, 2014,42(1):57-61.
11	Akinkuolie AO, Paynter NP, Padmanabhan L, et al. High-density lipoprotein particle subclass heterogeneity and incident coronary heart disease[J]. Circ Cardiovasc Qual Outcomes, 2014,7(1):55-63.
12	Chung M, Lichtenstein AH, Ip S, et al. Comparability of methods for LDL subfraction determination: A systematic review[J].Atherosclerosis, 2009,205(2): 342-348.
13	Kornerup K, Nordestgaard BG, Feldt-Rasmussen B, et al.Transvascular low-density lipoprotein transport in patients with diabetes mellitus (type 2): A noninvasive in vivo isotope technique[J].Arterioscler Thromb Vasc Biol, 2002,22(7):1168-1174.
14	Campos H, Walsh BW, Judge H, et al. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women[J]. J Clin EndocrinolMetab,1997,82(12):3955-3963.
15	Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced antioxidant content of metabolic precursors of small,dense low-density lipoproteins[J]. Am JMed, 2001, 110(2):103-110.
16	Hulthe J, Wiklund O, Bondjers G, et al. LDL particle size in relation to intima-media thickness and plaque occurrence in the carotid and femoral arteries in patients with hypercholesterolaemia[J]. J Intern Med, 2000,248(1): 42-52.
17	Campos H, Moye LA, Glasser SP, et al. Low-density lipoprotein size, pravastatin treatment, and coronary events[J]. JAMA,2001,286(12):1468- 1474.
18	Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype[J]. Curr Atheroscler Rep,2000,2(3):200- 207.
19	Grammer TB, Kleber ME, Ma^‥rz W, et al. Low-density lipoprotein particle diameter and mortality: the ludwigshafen risk and cardiovascular health study[J]. Eur Heart J, 2014,Feb 25[Epub ahead of print]
20	Otvos JD, Mora S, Shalaurova I, et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number[J]. J Clin Lipidol, 2011,5(2):105-113.
21	Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists[J]. J Clin Lipidol, 2011,5(5):338-367.
22	AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices, Cole TG, Contois JH, et al. Association of apolipoprotein B and nuclear magnetic resonance spectroscopyderived LDL particle number with outcomes in 25 clinical studies:assessment by the AACCLipoprotein and Vascular Diseases Division Working Group on Best Practices[J]. Clin Chem, 2013,59(5):752-770.
23	Howard WJ, Russell M, Fleg JL, et al. Prevention of atherosclerosis with LDL-C lowering-lipoprotein changes and interactions: The sands study[J]. J Clin Lipidol, 2009,3(5):322-331.
24	Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women[J]. Circulation, 2009,119 (7):931-939.
25	Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the framingham offspring study-implications for ldl management[J]. J Clin Lipidol,2007,1(6):583-592.
26	Paynter NP, Sesso HD, Conen D, et al. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women[J].Clin Chem, 2011,57(8): 1178-1187.
27	James W. Biological variation database, and quality specifications for imprecision, bias and total error (desirable and minimum)[DB/OL].2014 update. http://www.westgard.com/biodatabase-2014-update.htm.
28	Sniderman A, McQueen M, Contois J, et al. Why is non-highdensity lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol[J]? J Clin Lipidol,2010,4(3):152-155.
29	Elshazly MB, Martin SS, Blaha MJ, et al. Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: The vldl-2 study (very large database of lipids)[J]. J Am Coll Cardiol, 2013,62(21):1960-1965.
30	Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: A meta-analysis[J]. JAMA, 2012, 307(12):1302-1309.
31	Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk[J].Circ Cardiovasc Qual Outcomes, 2011,4(3):337-345.
32	Robinson JG, Wang S, Smith BJ, et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk[J]. J Am Coll Cardiol,2009,53(4):316-322.
33	Sniderman AD, Williams K, McQueen MJ, et al. When is equal not equal[J]? J Clin Lipidol, 2010,4(2):83-88.
34	Sniderman AD, Hogue JC, Bergeron J, et al. Non-HDL cholesterol and apob in dyslipidaemia[J]. Clin Sci, 2008,114(2):149-155.

[1]	Lu Li, Ye Tian, Yuanyuan Xie. Relationship of serum vitamin D, folic acid and blood lipid levels in pregnant women with preeclampsia [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(05): 607-614.
[2]	Wenhua Zhang, Jufeng Wei, Ling Li. Clinical significance of monitoring of adipocyte fatty acid-binding protein and blood fat levels in serum of preeclampsia pregnant women [J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2015, 11(01): 58-61.
[3]	Boxuan Zhou, Zhicheng Yao, Zhiyong Xiong, Ruixi Li, Tianxing Dai, Mingxing Xu, Weiming Fan, Zheng Zhou, Hao Liang, Meihai Deng, Yunbiao Ling. Clinical significance of apolipoprotein F in prognosis of patients with hepatocellular carcinoma [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(01): 73-76.
[4]	Ke Zhang, Zhanqi Yang, Wei Yan, Erming Zhang, Pingchao Xiang. Effect of continuous positive airway pressure on occurrence of cardiovascular and cerebrovascular events in patients with obstructive sleep apnea syndrome [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(05): 433-440.
[5]	Zhiqun Min, Hang Su. Association between aldehyde dehydrogenase 2 gene polymorphism and cardiovascular and cerebrovascular diseases in Guangzhou [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2024, 12(02): 97-102.
[6]	Jianwei Liu, Yan Wang. The relationship between cystatin C gene G73A locus and appolipoprotein E gene polymorphisms and vascular cognitive impairment [J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(02): 87-93.

Please choose a citation manager

Content to export